Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Neutral

Debt to Equity Rating

Sell

Price to Earnings Rating

Sell

Analyst Rating

Buy

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Buy

Wall Street Data Solutions Rating

Buy

A

Biogen Inc. Common Stock (BIIB)

Biological Products, (no Disgnostic Substances)

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

225 BINNEY STREET
CAMBRIDGE, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

09/17/1991

Market Cap

29,589,778,680

Shares Outstanding

144,900,000

Weighted SO

144,898,112

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

BMY --.--%

ABBV --.--%

MRK --.--%

GILD --.--%

JNJ --.--%

AMGN --.--%

PFE --.--%

SNY --.--%

NVS --.--%

Beta

-0.0380

Last Div

0.0000

Range

189.44-270.5

Chg

1.5100

Avg Vol

1047569

Mkt Cap

29589778680

Exch

NASDAQ

Country

US

Phone

617 679 2000

DCF Diff

-172.8477

DCF

375.8877

Div Yield

0.0000

P/S

3.1246

EV Multiple

13.8183

P/FV

1.8615

Div Yield %

0.0000

P/E

25.5284

PEG

-0.4134

Payout

0.0000

Current Ratio

2.2870

Quick Ratio

1.4807

Cash Ratio

0.6141

DSO

80.1004

DIO

342.2737

Op Cycle

422.3741

DPO

48.4163

CCC

373.9579

Gross Margin

0.7178

Op Margin

0.1424

Pretax Margin

0.1387

Net Margin

0.1223

Eff Tax Rate

0.1190

ROA

0.0432

ROE

0.0768

ROCE

0.0569

NI/EBT

0.8818

EBT/EBIT

0.9746

EBIT/Rev

0.1424

Debt Ratio

0.2419

D/E

0.4081

LT Debt/Cap

0.2837

Total Debt/Cap

0.2898

Int Coverage

6.5927

CF/Debt

0.2751

Equity Multi

1.6869

Rec Turnover

4.5568

Pay Turnover

7.5388

Inv Turnover

1.0664

FA Turnover

2.6026

Asset Turnover

0.3533

OCF/Share

12.2521

FCF/Share

10.0797

Cash/Share

13.1106

OCF/Sales

0.1884

FCF/OCF

0.8227

CF Coverage

0.2751

ST Coverage

9.2430

CapEx Coverage

5.6399

Div&CapEx Cov

5.6399

P/BV

1.8615

P/B

1.8615

P/S

3.1246

P/E

25.5284

P/FCF

20.1620

P/OCF

16.5801

P/CF

16.5801

PEG

-0.4134

P/S

3.1246

EV Multiple

13.8183

P/FV

1.8615

DPS

0.0000

Latest Headlines (EST)

The Motley Fool Mar 27, 13:15 Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025 GlobeNewswire Inc. Feb 05, 00:30 Global Water Flavouring Drops Market Poised for Substantial Growth, Projected to Reach USD 73.91 Billion by 2035 | Future Market Insights, Inc. GlobeNewswire Inc. Jan 26, 23:33 FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease GlobeNewswire Inc. Oct 27, 00:15 Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 GlobeNewswire Inc. Oct 24, 00:06 Sage Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 28, 2024 Deadline to file Lead Plaintiff Motion Benzinga Sep 10, 03:00 Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know GlobeNewswire Inc. Jun 27, 23:39 “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China GlobeNewswire Inc. Jun 09, 23:37 FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease The Motley Fool Jan 22, 13:39 Highlights From the 2024 JPMorgan Health Care Conference The Motley Fool Jan 18, 05:50 These Could Be the Biggest Nasdaq-100 Winners in 2024, According to Wall Street Benzinga Jan 10, 14:29 Analyst Assesses Cell-Programming Focused Ginkgo Bioworks' Positioning Amid Revenue Surge, Program Adjustments Investing.com Jan 09, 14:06 2 Low-Priced Gene Therapy Stocks to Speculate On MarketWatch Dec 30, 06:37 Nvidia tops list of Wall Street's 20 favorite stocks for 2024 MarketWatch Dec 30, 06:37 Nvidia tops list of Wall Street's 20 favorite stocks for 2024 MarketWatch Dec 27, 09:23 Nvidia tops list of Wall Street's 20 favorite stocks for 2024 MarketWatch Dec 26, 08:25 Nvidia tops list of Wall Street's 20 favorite stocks for 2024 GlobeNewswire Inc. Dec 19, 07:30 Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission GlobeNewswire Inc. Dec 15, 09:05 CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease GlobeNewswire Inc. Dec 14, 06:30 ZURZUVAEâ„¢ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. The Motley Fool Dec 09, 13:52 2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond

Revenue Product Segmentation